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NADPH oxidaseThis reviewhighlights the important role of redox signaling betweenmitochondria andNADPHoxidases. Besides
the deﬁnition and general importance of redox signaling, the cross-talk betweenmitochondrial and Nox-derived
reactive oxygen species (ROS) is discussedon the basis of 4 different examples. In theﬁrstmodel, angiotensin-II is
discussed as a trigger for NADPH oxidase activation with subsequent ROS-dependent opening of mitochondrial
ATP-sensitive potassium channels leading to depolarization of mitochondrial membrane potential followed by
mitochondrial ROS formation and respiratory dysfunction. This concept was supported by observations that
ethidium bromide-induced mitochondrial damage suppressed angiotensin-II-dependent increase in Nox1 and
oxidative stress. In another example hypoxia was used as a stimulator of mitochondrial ROS formation and by
using pharmacological and genetic inhibitors, a role ofmitochondrial ROS for the induction of NADPH oxidase via
PKCɛ was demonstrated. The third model was based on cell death by serum withdrawal that promotes the
production of ROS in human 293T cells by stimulating both the mitochondria and Nox1. By superior molecular
biological methods the authors showed that mitochondria were responsible for the fast onset of ROS formation
followed by a slower but long-lasting oxidative stress condition based on the activation of an NADPH oxidase
(Nox1) in response to the fast mitochondrial ROS formation. Finally, a cross-talk between mitochondria and
NADPHoxidases (Nox2)was shown innitroglycerin-induced tolerance involving themitochondrial permeability
transition pore and ATP-sensitive potassium channels. The use of these redox signaling pathways as
pharmacological targets is brieﬂy discussed.04.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Background of redox signaling
Redox signaling pathways play an important role in many ﬁelds of
biochemistry as well as medical research and provide the basis for
understanding (patho)physiological mechanisms [1–13]. They allow
establishing future strategies for interventions at the cellular level and
therapeutic principles in animals and humans. Many aspects of the
generation and regulation of redox signals by ROS derived from
NADPH oxidases andmitochondria as well as NOmetabolites fromNO
synthases are known [14]. However, many open questions remain
concerning the translation of (in most part harmful) free radical
reactions of superoxide, nitric oxide and their reaction products to
redox signals with cellular messaging character. The developments of
the last years show that mitochondria are associated in many aspects
with redox reactions [15–17]. Based on estimations up to 1% of the
electrons, which are involved in mitochondrial respiration, are
transferred to molecular oxygen [18]. Superoxide and its product
hydrogen peroxide, which are formed at the mitochondrial respira-tory complexes, were demonstrated to have important signaling
functions contributing to various disease states [19–21]. There is clear
experimental evidence that the pores and channels in the mitochon-
drial membrane as well as the membrane potential are important
regulators of efﬂux and inﬂux of ROS/RNS from and intomitochondria
[22–29]. The focus of the present review lies on the mechanisms by
which mitochondrial ROS activate NADPH oxidases [30–34] and vice
versa cytosolic ROS/RNS trigger mitochondrial oxidative stress and
dysfunction [29,35]. Given the importance of oxidative stress in
almost all cardiovascular, inﬂammatory and neurodegenerative
diseases the process of ROS-induced ROS formation gains high
importance for signaling processes in particular and pharmaceuti-
cal/clinical implications in general.
1.1. Oxidative stress and redox regulation
The discovery of superoxide dismutases (mitochondrial Mn-SOD
and cytosolic/extracellular Cu,Zn-SOD) by Fridovich et al. in the 1960s
[36] suggested that superoxide is formed in the organism and in living
cells. Moreover, the existence of SODs implied that superoxide which
is a harmful species involved in pathological processes forces the
organism to express SODs for protection. Based on these observations
until approximately 25 years ago, the accepted view of free radicals in
1 It should be noted that the term “uncoupling of mitochondrial respiration” is
usually used to describe distraction of mitochondrial electron ﬂow from ATP synthesis.
“uncoupling” is used here in the meaning of “autoxidation”.
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contribute to pathophysiological and harmful processes. Only for a
few exceptions, a physiological role of free radicals in biological
processes could be established (e.g. for monooxygenation reactions by
P450s) [37]. It was in the 1970s and 80s, after decades of intensive
search for the so-called “endothelium-derived relaxing factor” (EDRF)
which leads to the vasodilatation of the smooth muscle, when the
Noble Prize recipients Murad, Ignarro und Furchgott identiﬁed EDRF
as nitric oxide (•NO) [38–40]. This discovery changed the negative
view on free radicals in biology and established the understanding
that these species can also confer highly important physiological
processes and are involved in cellular signaling. The physiological role
of •NO in the vascular system and in the central and peripheral
nervous system was extensively reviewed [41–44].
The superoxide anion (•O2−) can be formed from different sources
such as xanthine oxidase, NAD(P)H oxidases, uncoupled NO synthases
and the mitochondrial respiratory chain. In many aspects it can be
regarded as a direct antagonist of •NO. A direct interaction between
•NO and superoxide could be proven by the existence of peroxynitrite
(ONOO−) that is formed by the diffusion-controlled reaction of •NO
with superoxide [45–48]. Peroxynitrite is a muchmore potent oxidant
than •NO and superoxide [49,50] and its contribution to cardiovascular
and neurodegenerative diseases is meanwhile accepted [51–58].
Moreover, the reactivity of •NO and superoxide is dramatically
changed upon formation of peroxynitrite [59,60]. Therefore, the
formation of peroxynitrite may be understood as the conversion of
the physiological, protective properties of •NO to those of peroxynitrite
which do rather contribute to pathophysiological and harmful
processes [61]. If the formation of oxidizing species such as superoxide
and peroxynitrite exceeds a certain limit, the cellular redox balance is
impaired and accordingly redox systems (e.g. the thiol–disulﬁde
equilibrium) are shifted to the oxidized condition and the cellular
antioxidant defense system (low molecular weight compounds such
as ascorbate or tocopherol but also high molecular weight enzymatic
systems such as superoxide dismutases or catalases) is overstrained
[62–64]. This condition is termed oxidative stress and, in the long-run
(e.g. under chronic inﬂammatory conditions) causes cell death
(apoptosis or necrosis) and death of the whole organism.
At low concentrations oxidants/free radicals may also confer
physiological functions in cellular signaling processes. A prominent
example is •NO itself, a potent regulator of vascular tone [65]. But also
superoxide and peroxynitrite are involved in redox signaling by
inhibiting or activating plenty of enzymatic systems by oxidative
protein modiﬁcations such as thiol oxidation [49,66,67], S-nitros(yl)
ation [68] and tyrosine nitration [69,70]. These oxidative protein
modiﬁcations (reviewed in [71]) induce secondary signal transduc-
tion processes in the cellular network. Examples for redox-regulated
proteins are the phosphatase calcineurin (oxidation/reduction at the
binuclear metal center) [7], modulation of protein expression at the
transcriptional level (oxidation/reduction zinc-ﬁnger motifs in
transcription factors) [72,73], sulfoxidation of tyrosines phosphatases
[74], modulation of the activity of cyclooxygenase (COX-1 and COX-2)
and thereby the formation of prostaglandins and thromboxanes [75],
modulation of mitochondrial electron transport and the respiratory
chain (oxidation/reduction of iron–sulfur-cluster) [18,76] as well as
the activation of protein kinase C by hydrogen peroxide [77].
Prostacyclin synthase is tyrosine-nitrated and inactivated by perox-
ynitrite in the low micromolar range [69,78,79] but until now, the
reversibility of this inactivation by so-called denitratases lacks a
biological proof [80–89]. Also the superoxide- and peroxynitrite-
triggered proteasomal degradation of GTP-cyclohydrolase-1 may be
regarded as a redox event and considerably inﬂuences vascular
function [90,91]. More vascular and non-vascular redox events of
superoxide are reviewed in [20,92–94]. Maybe these identiﬁed and
the yet unidentiﬁed physiological functions of reactive oxygen and
nitrogen species (ROS and RNS) are much more important than thecontribution of these reactive species to pathophysiological processes
as observed under oxidative stress conditions [95,96].
ROS and RNS are important mediators of inﬂammation that are
essential for immune response and host defense. Leukocytes (such as
monocytes and neutrophils) are loaded with enzymatic systems that in
response to an inﬂammatory stimulus generate a burst of reactive
oxygen and nitrogen species (from inducible NO synthase and NADPH
oxidases) exceeding the normal physiological range by far [97].
Endotoxins (e.g. from bacteria) can not only induce NOS-2 in white
blood cells (e.g.macrophages) but also in smoothmuscle cells leading to
•NO levels in the high nanomolar range (and up to 100 µM intracellular
nitrite) [98–100]. In the setting of septic shock this uncontrolled •NO
formation together with other mediators can cause uncontrolled, life-
threatening hypotension (drop in blood pressure). Endotoxins also
stimulate NADPH oxidases in these cells (by translocation of cytosolic
regulatory subunits to themembrane-boundgp91phox catalytic subunit)
resulting in an “oxidative burst” and huge amounts of ROS and RNS. The
high concentrations of superoxide and •NO produced in these cells lead
ultimately to the formation of peroxynitrite [101,102].1.2. Redox signaling: bioinorganic chemistry at its best
The title of this chapterwas taken froma review article of Ullrich and
Kissner since it reﬂects the elegance of the redox signalingprocesses and
the way how nature uses harmful reactive species for the beneﬁt of life
[14]. Interactions of the radicals •NO and superoxide form a redox
systemwhich includes nitros(yl)ations and nitrations and is part of the
complex cellular signaling network. In addition, transition metal
chemistry is also deeply involved because •NO, superoxide and
peroxynitrite form metal complexes, which affect their reactivity.
Hence, redox regulation has become an interest to bioinorganic
chemists. In summary, superoxide causes vascular dysfunction not
only by its direct effect on •NO bioavailability or formation of
peroxynitrite and subsequent oxidative depletion of tetrahydrobiop-
terin (BH4) [103] but also by changing the prostanoid proﬁle to a
vasoconstrictive, pro-aggregatory, pro-atherosclerotic phenotype. Due
to a different focus of the present review, these concepts were only
brieﬂy discussed here. The reader will ﬁnd more information on these
ideas in the review of Ullrich and Kissner [14] aswell as in other reviews
highlightingmore the physiological [3] or chemical [104] aspects of this
topic.1.3. Mitochondrial pathways in redox signaling
Mitochondria are a perfect ampliﬁer of ROS and RNS formation by
several mechanisms: First, any oxidative damage at the constituents
of the mitochondrial respiratory chain (e.g. by reaction with iron–
sulfur-centers or critical thiols in complexes I and II but also
associated proteins such as the aconitase) will lead to “uncoupling”1
of the mitochondrial respiration with subsequent transfer of electrons
to molecular oxygen increasing the mitochondrial superoxide/
hydrogen peroxide formation in a positive feedback fashion [105].
Second, increased mitochondrial peroxynitrite formation will ulti-
mately lead to nitration and inactivation of manganese superoxide
dismutase (MnSOD) [70,106], which results in the impaired break-
down of mitochondrial superoxide further feeding the vicious cycle.
Third, mitochondrial ROS formation itself may be stimulated by
cytosolic ROS/RNS (e.g. by opening of the redox sensitive KATP
channels) leading to changes in the mitochondrial membrane
potential [29], an important determinant of mitochondrial ROS
generation, as discussed below.
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criticality” which in some situations determines between life and
death [107]. These are oscillations in mitochondrial energetics,
inducing a state in which the mitochondrial network of cardiomyo-
cytes becomes very sensitive to small perturbations in ROS, resulting
in the scaling of local mitochondrial uncoupling and ΔΨm loss to the
whole cell [108]. There is good evidence that these phenomena
contribute to the genesis of potentially lethal cardiac arrhythmias in
the heart during ischemia and reperfusion [109].
Since the present review will concentrate on mitochondrial redox
signaling, the composition and redox sensitivity of two mitochondrial
channels/pores will be discussed in detail (reviewed in [105]).
Mitochondrial protein complexes that participate in critical mito-
chondrial/cellular processes, contain inner membrane proteins with
critical vicinal thiols that can be readily oxidized by peroxynitrite
[110,111]. The mitochondrial permeability transition pore (mPTP)
itself is subject to redox regulation (Fig. 1) [105]. Its major
constituents are the voltage-dependent anion channel (VDAC), the
adenine nucleotide translocase (ANT) and the matrix-located regu-
latory subunit cyclophilin D (CypD). ANT is known to be affected by
oxidants including peroxynitrite [111,112]. ANT can form a complex
with the outer membrane protein VDAC, and oxidation of ANT vicinal
thiols leads to the translocation of CypD, forming the basic unit of the
pore. Oxidant-stimulated formation of VDAC–ANT–CypD complex
triggers mPTP opening and promotes the release of pro-apoptotic
proteins to the cytosol [110]. Peroxynitrite leads to mPTP opening
[111,113,114], a process that is partially based on oxidation of critical
thiols in ANT [111]. Peroxynitrite may also nitrate essential tyrosines
in VDAC [115], which contributes to the formation of the active mPTP
complex and/or opening of the pore. These processes also underlie
the phenomenon of ischemic preconditioning, a scenario in which
brief intermittent periods of ischemia provide protection against
subsequent ischemic injury [116]. It is meanwhile well understood
that mPTP plays a critical role in mitochondrial redox signaling, which
is involved in ischemic preconditioning [117–119]. A number of
studies show, that ROS formation is essential for ischemic precondi-
tioning [26,27,120] and that protective effects of this phenomenon are
lost upon addition of antioxidants [121,122]. Also the involvement of
themPTP is well deﬁned since genetic deletion of CypD resulted in the
loss of protective effects elicited by ischemic preconditioning
[117,119], indicating that mPTP is essential for mitochondrial ROS
(especially hydrogen peroxide) release [118,123].
In an informative editorial, R.P. Brandes has discussed the role of
NADPH oxidase-derived cytosolic ROS in triggering mitochondrial
ROS formation [29]. This concept is based on the generation ofFig. 1. Constituents and oxidative opening of the mPTP. Tyrosine nitration of the
voltage-dependent anion channel (VDAC), disulﬁde formation in the adenine
nucleotide translocase (ANT) and translocation of the matrix-located regulatory
subunit cyclophilin D (CypD) increase the opening probability of the mPTP and the
release of apoptosis-inducing factors (AIF). Adopted from Radi et al. [105].cytosolic ROS by NADPH oxidases and subsequent reaction of
superoxide with the mitochondrial ATP-sensitive potassium channels
(mtKATP) in the mitochondrial membrane (Fig. 2) [124]. Upon mtKATP
opening the electrophoretic inﬂux of potassium cations into the
matrix causes depolarization of themitochondrial membrane (Δψm ↓)
along with matrix swelling and alkalinization [125]. Matrix alkalin-
ization in turn has been suggested to be responsible for the increase in
H2O2 formation observed in cardiomyocytes treated with the mtKATP
opener diazoxide [126–128]. In their original research paper, Kimura
et al. have shown that angiotensin-II triggered activation of NADPH
oxidases in the myocardium confers ischemic preconditioning, which
was blocked by the NADPH oxidase inhibitor apocynin [129]. The
protective effect of angiotensin-II on lipid peroxidation and p38 MAP
kinase activation in the myocardium was also lost when mtKATP
channels in cardiac myocytes were blocked by 5-hydroxydecanoate
(5-HD). In addition, angiotensin-II dependent ROS formation from
cardiac myocytes was suppressed by 5-HD although this compound
had no effect on oxidative burst in isolated leukocytes. The role of
ROS in this process was previously demonstrated by inhibition
of pharmacological preconditioning by exogenously added ROS via
5-HD-induced blockade of the mtKATP channels [128]. These observa-
tions indicate that mitochondria are an important constituent of the
positive feedback loops leading to an ampliﬁcation of ROS production
and ROS-dependent signaling. In the next chapters I will present some
ideas from recent studies on how mitochondria are involved in redox
signaling and ROS-triggered ROS.Fig. 2. Angiotensin-II triggered activation of NADPH oxidases with subsequent opening
of mitochondrial KATP channels by Nox-derived ROS and mitochondrial ROS release via
mPTP represent an ampliﬁcationmechanism for angiotensin-II induced oxidative stress
and contribute to angiotensin-II mediated preconditioning via p38 MAPK and JNK
pathway. Adopted from Brandes [29].
Fig. 3. Proposed model of angiotensin-II induced mitochondrial dysfunction via
kindling radicals from NADPH oxidase. These Nox/NOS-derived ROS and RNS open
the mtKATP channels decreasing the mitochondrial membrane potential which results
in “uncoupling” of mitochondrial respiration. Mitochondria release H2O2, which in turn
further activates NADPH oxidase via PKC, resulting in increased intracellular superoxide
production, reduced •NO bioavailability and ﬁnally endothelial/vascular dysfunction.
Adopted from Doughan et al. [35].
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induced hypertension
2.1. Molecular mechanisms of angiotensin II-mediated mitochondrial
dysfunction: linking mitochondrial oxidative damage and vascular
endothelial dysfunction
In their recent publication Doughan et al. from the group of
S. Dikalov proposed a new mechanism on how NADPH oxidase
derived superoxide and hydrogen peroxide trigger mitochondrial
dysfunction and ROS formation via the KATP channel [35]. For this
purpose the authors used angiotensin-II treated endothelial cells (an
experimental ex vivo model of hypertension). The authors started out
with measurements of hydrogen peroxide release from isolated
mitochondria from bovine aortic endothelial cells (BAECs) by EPR and
amplex red/peroxidase ﬂuorescence. All treatments were performed
with intact cells, then mitochondria were isolated and subjected to
analysis. Angiotensin-II increased H2O2 release which was blocked by
the NADPH oxidase inhibitor apocynin, the PKC inhibitor chelerythr-
ine, the radical scavenger uric acid, the KATP channel blockers 5-HD or
glibenclamide as well as the NOS inhibitor L-NAME. Stimulation of
mitochondrial electron ﬂow always led to similar observations
regardless whether substrates of complex I (malate/glutamate) or
complex II (succinate) were used. Angiotensin-II or phorbol ester had
no effect on ROS production in isolated mitochondria itself, indicating
that cytosolic/membranous components are involved. The purity of
mitochondrial preparations was probed by Western blotting using
antibodies against GAPDH (cytosolic), cytochrome c oxidase (mito-
chondrial) and p22phox (membranous). The increase in H2O2
production in mitochondria from angiotensin-II treated BAECs was
suppressed by the knock-down of the NADPH oxidase subunit p22phox
by siRNA. Blockade of the mPTP by cyclosporine A decreased the H2O2
release from the mitochondria isolated from angiotensin-II treated
BAECs. The importance of the mitochondrial membrane potential was
demonstrated by the effect of the K+/H+ antiporter nigericin.
Mitochondrial membrane potential collapsed in the mitochondria
from angiotensin-II treated cells (detected by JC-1 ﬂuorescence) and
was normalized by apocynin, uric acid, ebselen (a GPxmimetic), 5-HD
and glibenclamide and collapsed completely upon addition of the KATP
channel opener diazoxide. Mitochondrial respiration (states 3 and 4
as well as RCR) was impaired and mitochondrial GSH levels were
decreased by angiotensin-II treatment and normalized by apocynin,
5-HD and glibenclamide. Nitric oxide formation (measured by EPR-
based detection of Fe(DETC)2) in BAECs was decreased by angioten-
sin-II treatment and rescued by uric acid and 5-HD. With this study,
Dikalov et al. provide a new hypothesis on the sequence of
pathogenesis in the setting of hypertension and a detailed picture of
the cross-talk between cytosolic and mitochondrial ROS sources
(Fig. 3): Angiotensin-II activates NADPH oxidases in the cytoplasmic
membrane and subsequent ROS formationwill activate mitochondrial
KATP channels leading to depolarization of mitochondrial membrane
potential. Decreased Δψm confers increased mitochondrial ROS
formation and mPTP opening. Mitochondrial ROS (most probably
hydrogen peroxide) activate PKC triggering the vicious cycle of
NADPH oxidase activation. By this mechanism mitochondria act as an
ampliﬁer for an oxidative stress positive feedback loop.
2.2. Cross-talk between mitochondria and NADPH oxidase: effects of
mild mitochondrial dysfunction on angiotensin-II mediated increase in
Nox isoform expression and activity in vascular smooth muscle cells
Recently, Wosniak et al. from the laboratory of F.R.M. Laurindo
revealed a new mechanism on how mild mitochondrial dysfunction
regulates angiotensin-II dependent activation of NADPH oxidases in
vascular smooth muscle cells (VSMCs) [32]. For this purpose VSMCs
were treated with low concentrations of ethidium bromide (EtBr,250 ng/ml). Despite appreciable loss of mtDNA (pseudo ρ0 cells), VSMC
remained viable, had only 29% less oxygen consumption and 16%
greater baseline hydrogen peroxide but unchanged glutathione levels.
Most strikingwas the observation that angiotensin-II triggered increase
in membrane NADPH oxidase activity (measured by lucigenin-derived
chemiluminescence as well as dihydroethidine-derived 2-hydroxyethi-
dium formation) was lost in EtBr treated cells along with failure to
upregulate Nox1 mRNA. As a possible explanation, protein disulﬁde
isomerase, an NADPHoxidase regulator, exhibited increased expression
and inverted pattern of migration to membrane fraction after EtBr.
These results unravel functionally relevant cross-talk between mito-
chondria and NADPH oxidase, which markedly affects redox responses
to angiotensin-II at the transcriptional level.
3. Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2+]i
through the mitochondrial ROS-PKCε signaling axis in pulmonary
artery smooth muscle cells
In their recent publication, Rathore et al. from the group of Y.-X.
Wang have identiﬁed the molecular mechanisms by which mitochon-
drial ROS activate PKCε leading to activation ofNADPHoxidases [31]. For
this purpose the authors usedmousepulmonary arteries. In theﬁrst part
of the study itwas shown that hypoxia activatesNADPHoxidase activity
(most probably Nox1) in these vessels by increased translocation of
p47phox to the plasma membrane. It should be noted that hypoxia/
reoxygenation (equivalent to ischemia/reperfusion) involves many
mitochondrial processes such as mitochondrial ROS formation
[16,130,131]. Pharmacological (apocynin) and genetic (p47phox−/−)
inhibitions of NADPH oxidase signiﬁcantly attenuated the hypoxic
increase in ROS formation (DCF ﬂuorescence) and membranous Nox
activity in freshly isolatedmouse pulmonary artery smoothmuscle cells.
Hypoxia-induced Nox activation and intracellular ROS formation were
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chelerythrine, with a speciﬁc PKCε translocation peptide inhibitor but
not with GÖ6976, an inhibitor shown to block conventional, but not
novel, PKC isozymes. In addition to pharmacological inhibition, genetic
deletion of PKCε (PKCε−/−mice) abolished the effect of hypoxia onNox
activity and intracellular ROS formation. Inhibition ofmitochondrial ROS
generation with rotenone or myxothiazol blocked the hypoxia-induced
increase in Nox activity. Further support for an essential role of
mitochondria-derived ROS in this signaling process came from experi-
ments demonstrating that enhanced mitochondrial and cytosolic H2O2
decomposition by GPx-1 gene overexpression (GPx-1tg) prevented,
whereas inhibition of mitochondrial and cytosolic H2O2 breakdown by
GPx-1 gene deletion (GPx-1−/−) augmented the hypoxia-induced
increase in Nox activity in pulmonary arteries. Finally, it was
demonstrated that exogenously added H2O2 also increased Nox activity
in thepulmonary arteries. This studyused elegant experimentsbasedon
different speciﬁc inhibitors of PKCε, Nox-subunit and GPx-1 knockout
mice to demonstrate ROS (H2O2)-driven signaling in the setting of
hypoxia (Fig. 4). It should be noted that under hypoxic conditions •NO
can be easily generated from nitrite resulting in peroxynitrite formation
in the presence of superoxide. Indeed, the study by Rathore et al. does
not disprove a role of peroxynitrite but only demonstrates that
superoxide is involved and a species that is scavenged by GPx, a well-
known sink for peroxynitrite [132].4. Link between mitochondria and NADPH oxidase 1 isozyme for
the sustained production of reactive oxygen species and cell death
In a previously published study Lee et al. from the group of H.-D. Um
have shown that serumwithdrawal promotes the production of ROS in
human293T cells by stimulating both themitochondria andNox1 [133].
An analysis of their relationship revealed that themitochondria respond
to serumwithdrawal within a few minutes, and the ROS (measured by
ﬂow cytometry using dichloroﬂuorescein ﬂuorescence) produced by
the mitochondria triggers Nox1 action by stimulating phosphoinositide
3-kinase (PI3K, by Western blotting) and Rac1. Activation of the PI3K/
Rac1/Nox1 pathwaywas evident 4–8 h after but not earlier than serum
withdrawal initiation, and this time lag was found to be required for an
additional activator of the pathway, Lyn (proven by siRNA), to be
expressed. Cycloheximide and actinomycin D, which inhibit protein
synthesis and transcription, respectively, were used to examine the
important role of gene transcription and enzyme expression in this
process. Functional analysis suggested that, although the mitochondria
contribute to the early (0–4 h) accumulation of ROS, themaintenance ofFig. 4. Proposed model of hypoxia-induced NADPH oxidase activation by mitochondrial
H2O2 release. The effect of hypoxia on NADPH oxidase activity was demonstrated by the
Nox inhibitor apocynin and p47phox knockout. The role of PKCε was demonstrated by
speciﬁc inhibitors and PKCε knockout. The important contribution of mitochondrial
ROS was shown by suppression of hypoxia effects by rotenone and by GPx-1
overexpression and deletion. Based on the results of Rathore et al. [31].the induced ROS levels to the later (4–8 h) phase required the action of
the PI3K/Rac1/Nox1 pathway. Serum withdrawal-treated cells even-
tually lost their viability, which was reversed by blocking either the
mitochondria-dependent induction of ROS using rotenone or KCN or
the PI3K/Rac1/Nox1 pathway using the dominant negative mutants
(PI3K-M, Rac1-M) or small interfering RNAs. This suggests that
mitochondrial ROS is an essential trigger but not enough to promote
cell death, which requires the sustained accumulation of ROS by the
subsequent action of Nox1. Contribution of Nox2 and Nox4 was
excluded by a lack of effect of siRNAs for these genes. Overall, this
study shows a signaling link between the mitochondria and Nox1,
which is crucial for the sustained accumulation of ROS and cell death in
serum withdrawal- induced signaling (Fig. 5).5. Cross-talk between reactive oxygen species from mitochondria
and NADPH oxidases — implications for endothelial dysfunction
associated with nitrate tolerance and aging
The last example of redox signaling between mitochondria and
NADPH oxidases is based on a report of Wenzel et al. from the
laboratory of A. Daiber (Fig. 6) [30]. Redox signaling was observed in
an animal model of nitroglycerin-induced nitrate tolerance, an
experimental model of vascular oxidative stress and dysfunction
and of the interactions of nitric oxide, superoxide and peroxynitrite
[134–137]. Organic nitrates need to undergo bioactivation to confer
their vasodilatory effects via nitric oxide or an NO-related species (e.g.
S-nitrosothiols and heme-NO) [138]. Due to pharmacologically
undesired side-reactions (e.g. NO could block cytochrome c oxidase)
there is simultaneous formation of superoxide [139]. Sources of
superoxide include organic nitrate-induced “uncoupling” of the
mitochondrial respiratory chain [140,141] as well as organic nitrate-
triggered activation of the renin–angiotensin–aldosterone system
(RAAS) and resulting PKC-dependent activation of vascular NADPH
oxidases [142,143]. The simultaneous formation of •NO and superox-
ide leads to an increase in peroxynitrite levels inducing inhibition of
the mitochondrial aldehyde dehydrogenase (ALDH-2) by thiol
oxidation [8,144], desensitization of soluble guanylyl cyclase and
subsequent impaired •NO down-stream signaling by thiol oxidation
[145], decrease in •NO bioavailability by direct trapping of •NO by
superoxide, uncoupling of NO synthase by peroxynitrite-triggered
depletion of its co-factor tetrahydrobiopterin (BH4) [146] as well as
inhibition of prostacyclin synthase by peroxynitrite-dependent
tyrosine nitration [147]. All of these events contribute to nitrate
tolerance and cross-tolerance (endothelial dysfunction) [137] andFig. 5. Serum withdrawal induces two pathways, one leading to the mitochondrial
production of ROS and the other leading to Lyn expression. Although the former event
occurs immediately after serum withdrawal, the latter is evident 4 h later. PI3K is then
activated in a mitochondrial ROS and Lyn-dependent manner. The activated PI3K in
turn stimulates Nox1 by inducing the translocation of Rac1 to membrane fractions and
the Rac1/Nox1 interaction. Consequently, the accumulation of ROS is extended into the
late phase (4–8 h), and cells lose their viability. Adopted from Lee et al. [133].
Fig. 6. Proposed hypothetical scheme of the cross-talk between mitochondrial and cytosolic (NADPH oxidase-derived) reactive oxygen and nitrogen species in the setting of nitrate
tolerance. ALDH-2, mitochondrial aldehyde dehydrogenase; CsA, cyclosporin A; Rot, rotenone; mPTP, mitochondrial permeability transition pore; APO, apocynin; Glib,
glibenclamide; Diaz, diazoxide; PGIS, prostacyclin synthase; sGC, soluble guanylyl cyclase; eNOS, endothelial NO synthase; PKC, protein kinase C; KATP, ATP-dependent potassium
channel. Adopted from Wenzel et al. [30].
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for the tolerance-free organic nitrate pentaerithrityl tetranitrate
[121,148–150] or by co-therapy with exogenously added antioxidants
such as hydralazine or lipoic acid [8,151].
The involvement of mitochondrial superoxide formation as well as
hydrogen peroxide signaling in nitrate tolerance was previously
demonstrated at the molecular level using MnSOD+/− and GPx-1−/−
mice [135,141,152]. Both deﬁciencies ampliﬁed nitroglycerin-induced
cross-tolerance to endothelium-dependent vasodilators (endothelial
dysfunction) whereas GPx-1 deﬁciency only caused impaired endothe-
lial function (decreased acetylcholine response) but showednoeffect on
nitroglycerin potency (nitrate tolerance). Further support for a role of
mitochondrial ROS in nitrate tolerance came from Esplugues et al. using
mitochondria-targeted antioxidants (Mito-Q and a GSH-ester) and cells
with depleted mitochondrial proteins (so-called ρ0 cells) [140]. These
observations are in accordance with our recently published concept on
how nitroglycerin–induced mitochondrial ROS formation via the
permeability transition pore activates cytosolic NADPH oxidases,
leading to endothelial dysfunction [30]. Surprisingly, endothelial
dysfunction (sensitive to NADPH oxidases) and vascular dysfunction
(sensitive tomitochondria)were dependent on the activation of distinct
oxidant sources, a ﬁnding supported by the fact that gp91phox−/− and
p47phox−/−mice developed tolerance but no endothelial dysfunction in
response to nitroglycerin treatment. The mechanism underlying this
concept is based on mtROS-driven PKC activation which in turn will
activate NADPH oxidases. The NADPHoxidase-dependent cytosolic ROS
and RNS formation will then uncouple eNOS, nitrate prostacyclin
synthase and desensitize sGC. Previous experimental studies have
shown that increased oxidative stress in cellular tissue per se is able to
activate the oxidase in a positive feedback fashion [153]. This cross-talk
was further substantiated by the observation that it was blocked by in
vivo and ex vivo administrations of themitochondrial permeability pore
inhibitor cyclosporine A, which selectively improved endothelial
dysfunction, whereas nitrate tolerance was not affected. This fully
agrees with our concept that mitochondrial hydrogen peroxide or
peroxynitrite is a potent trigger of NADPH oxidase activation and
subsequent NOS uncoupling. Blockade of mPTPwill remove this trigger.
However, cyclosporineA does not decrease nitroglycerin-induced intra-
mitochondrial oxidative stress, it rather trapsROSandRNS in thematrix,
explaining its lack of effect on nitrate tolerance. In contrast, the
respiratory complex I inhibitor rotenone improved endothelial dys-
function and tolerance since it removes mitochondrial oxidative stress,which largely contributes to nitrate tolerance by oxidative inhibition of
ALDH-2, and removes the trigger for NADPH oxidase activation in the
cytosol.
Finally, we were able to demonstrate a feedback redox signaling
from the cytosol to themitochondria: In vivo or ex vivo treatment with
the KATP opener diazoxide caused a nitrate tolerance-like phenomenon
in control animals, whereas the KATP inhibitor glibenclamide improved
tolerance in nitroglycerin-treated animals. These observations indicate
that maybe the essential step in nitroglycerin-triggered nitrate
tolerance is the induction of a vicious cycle consisting of mitochondrial
andNox-derived ROS/RNS formationwith each stimulating the other in
a positive feedback fashion. Very similar effects of rotenone (Rot),
cyclosporine A (CsA), diazoxide (Diaz) and glibenclamide (Glib) in an
experimental model of angiotensin-II induced hypertension have been
discussed above in detail [35]. A role of KATP channels for NADPH
oxidase-driven activation of mitochondrial ROS formation via changes
in themembrane potential was previously proposed and also discussed
above [29]. One may also speculate that in a second pathway,
nitroglycerin via its hypotensive action may cause an activation of the
renin–angiotensin–aldosterone system [154], leading to increased
circulating levels of angiotensin-II and aldosterone, and therefore to
anactivation of theNADPHoxidase. This concept is further corroborated
by the demonstration that in vivo treatment with an AT1 receptor
blocker was able to prevent the development of nitroglycerin-induced
endothelial dysfunction in an animalmodel of nitrate tolerance [155]. In
addition, our present ﬁndings could explain why treatmentwith an AT1
receptor blocker was not able to prevent the development of
nitroglycerin-induced nitrate tolerance in human subjects [156,157].
We propose that a similar cross-talk exists in the aging vasculature
and that aging-induced mtROS can activate cytosolic ROS/RNS
sources leading to age-related vascular dysfunction [158]. This
proposal is based on the ﬁnding that mtROS formation increases
with age (and is higher in MnSOD+/−mice) and endothelial function
is impaired with age (to a higher extend in MnSOD+/− mice). There
was a highly signiﬁcant inverse correlation between mitochondrial
ROS formation and endothelial function as well as mitochondrial ROS
formation and mitochondrial DNA damage. Considering the fact that
most ROS sources have redox switches, a cross-talk between all
known ROS sources may be possible: The interaction of mitochondria
and NADPH oxidases was just discussed above, but also eNOS can be
uncoupled by oxidative stress and depletion of the essential co-factor
BH4 [103]or oxidation of a critical zinc–thiolate-center [159] functions
Fig. 7. Proposed concept of cross-talk of different ROS and RNS sources.
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oxide, superoxide or peroxynitrite. The same applies for xanthine
oxidoreductase since the dehydrogenase form requires oxidative and
proteolytic modiﬁcations to become the oxidase form generating
superoxide [160–163]. Accordingly, it is not surprising that in many
disease states all sources of ROS are active. For example, we have
observed increased NADPH oxidase activity, mitochondrial ROS
formation, eNOS uncoupling and high serum xanthine oxidase activity
in experimental diabetes [164–166]. The concept of ROS-triggered
ROS may therefore be extended to all known sources of ROS (Fig. 7).
6. Outlook/Perspective
Hopefully, this review could demonstrate the importance of redox
signaling in physiology and disease. Besides the role of NADPH oxidases
and xanthine oxidase, mitochondria are of great importance since, even
when not directly affected or involved in a disease state, they may
become involvedby the abovedescribed cross-talk pathways and confer
an ampliﬁcation mechanism for cellular oxidative stress. In the future,
redox signaling may be an attractive target for drug development, but,
due to its complexity requires careful evaluation and understanding of
thepathways involved since blockade at thewrong target couldnot only
improve disease states but also suppress physiologically important
signaling pathways with detrimental consequences. The development
of mitochondria-targeted antioxidants and use of these new tools may
for management of disease and pathophysiological complications
[140,167–172] may show the direction for future strategies to mimic
the antioxidant defense system of the organism, which until now, was
rather traced by quite simple and primitive attempts [173–177]. A very
promising strategy may be based on the control of mitochondrial
channels such as the mPTP or the mtKATP [117,125], considering that a
pharmacological role of these channels beyond cardiac protection and
ischemia reperfusion seems plausible.
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